Clinical trial NCT00325728: Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
Official title: A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Insomnia
Keywords: Chronic Insomnia
Sleep Initiation and Maintenance Disorder
Drug Therapy
Alzheimer disease
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2006-05-15
Enrollment: 74
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance

Detailed description: Epidemiological data for 2005 show that an estimated 4.2 million people in the US suffer from Alzheimer's disease, often necessitating caregiver assistance, which can in many cases progress to institutionalization. Subjects with Alzheimer's disease dementia frequently experience disturbed sleep patterns characterized by insufficient nocturnal sleep and excessive daytime napping, which has been associated with both cognitive and behavioral pathology such as impaired daytime functioning, agitation, and nocturnal wandering.

Although the causality of sleep disturbances in Alzheimer's disease remains unclear; some research suggests that the fragmented sleep and associated behavioral disturbances could be related to the degeneration of the serotonergic and noradrenergic innervation of suprachiasmatic nucleus andsubsequent disruption in melatonin secretion patterns. Additionally, research suggests that melatonin levels are decreased in patients with Alzheimer's disease

In the United States, ramelteon is marketed for the treatment of insomnia characterized by difficulty with sleep onset and is under global development for the treatment of transient, chronic insomnia and circadian rhythm sleep disorders. It is believed that ramelteon works by binding melatonin to MT1/MT2 receptors in the suprachiasmatic nucleus which inhibits firing of specific neurons, which is thought to attenuate the alerting signal and allows the homeostatic mechanism to express itself and promote sleep.

Study participation is anticipated to be about 11 weeks (approximately 3 months).

Eligibility criteria: Inclusion Criteria

* Clinical diagnosis of dementia of the Alzheimer's type (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised) or probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related
* Disorders Association criteria.
* Female subjects must be post-menopausal.
* Stable residence with no planned move during the entire investigation period.
* Residing in the same residence with a responsible spouse, family member, or a professional caregiver who is present during the night who would agree to assume the role of the principal caregiver for the duration of the protocol period.
* Able to ingest oral medication and participate in all scheduled evaluations.
* Clinical laboratory evaluations (including clinical chemistry, hematology, and urinalysis) within the reference range as tested by the designated laboratory unless the results are deemed not clinically significant by the investigator or sponsor.
* Treatment medications for any non-excluded medications or concurrent medical conditions are stable for 30 days prior to the screening visit and medication(s) can in the investigator's judgment, remain stable throughout the duration of the study.
* Mini-Mental State Examination score of 8 to 28, inclusive.
* History of greater than or equal to 2 sleep disorder behaviors, occurring at least once weekly over the two weeks before screening.
* Actigraphy evidence shows a nighttime total sleep time of less than 7 hours per night based on at least 4 out of 7 nights of complete actigraphy data collected over the single-blind, placebo run-in period.
* Habitual bedtime of between 8 PM and 12 AM.

Exclusion Criteria

* Non-ambulatory, wheel chair bound or confined to bed and is without a consistent caregiver who is present during the night who could function as the primary caregiver.
* Caregiver is deemed by the investigator to be unreliable to supervise the wearing of the actigraphy, to complete the sleep log, to administer medication at the proper time, to bring the subject to the scheduled visits or to answer questions regarding the subject's condition or medication use.
* Lacks a mobile upper extremity to which to attach an actigraphy.
* Currently participating or has participated in another clinical study within the past 30 days.
* Demonstrates an unwillingness to abstain from caffeine after 2:00 PM for the duration of the clinical trial participation.
* Demonstrates an unwillingness to comply with the maximum limit of two alcoholic drinks per day and only one alcoholic drink after 6:00 PM for the duration of the protocol.
* Uses tobacco products or any other products during nightly awakenings that may interfere with the sleep wake cycle.
* History of drug abuse or tests positive for the presence of illicit drugs.
* Donated more than 400 mL of blood within the 90 days preceding the beginning of the study.
* Diastolic blood pressure greater than 95 mm Hg or a systolic pressure of greater than 160 mm Hg.
* Body mass index of greater than 36.
* Alanine transaminase level of greater than two times the upper limit of normal, active liver disease, jaundice or any clinically significant abnormal laboratory findings as determined by the investigator.
* History of a hypersensitivity or allergies to Ramelteon or melatonin.
* History of contraindications as noted in the Ramelteon label
* History of significant stroke or vascular dementia.
* History of severe renal dysfunction or disease.
* History of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not include those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin.)
* Any clinically significant movement disorder including but not limited to: akinesia, periodic limb movement disorder, restless leg syndrome, epilepsy, uncontrolled Parkinson's disease, or severe benign prostatic hyperplasia, cardiac asthma, chronic obstructive pulmonary disease.
* Rapid eye movement behavior disorder or sleep apnea.
* Any pain syndrome affecting sleep.
* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

  * Fluvoxamine
  * Melatonin
  * Rifampicin

Primary outcomes:
measure: Mean Nighttime Total Sleep Time as determined by actigraphy.
timeFrame: Week 1
Secondary outcomes:
measure: Change from Baseline in Nighttime Total Sleep Time
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Change from Baseline in Nighttime Wake After Sleep Onset per Actigraphy
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Change from Baseline in Nighttime Number Of Awakenings per Actigraphy
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Change from Baseline in Daytime Total Sleep Time
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Change from Baseline in the ratio of Daytime Total Sleep Time to Nighttime Total Sleep Time.
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Change from Baseline in Sleep Efficiency.
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Percentage of subjects who experience Increase in Nighttime Total Sleep Time of 30 minutes.
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
measure: Number of Daytime Naps.
timeFrame: Weeks 2, 4, 6, and 8 or Final Visit
Other outcomes:
Locations:
city: Alabaster
country: United States
state: Alabama
city: Huntsville
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Sun City
country: United States
state: Arizona
city: Tucson
country: United States
state: Arizona
city: Costa Mesa
country: United States
state: California
city: Fresno
country: United States
state: California
city: Irvine
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: National City
country: United States
state: California
city: Oxnard
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Francisco
country: United States
state: California
city: Darien
country: United States
state: Connecticut
city: Waterbury
country: United States
state: Connecticut
city: Boynton Beach
country: United States
state: Florida
city: Bradenton
country: United States
state: Florida
city: Brooksville
country: United States
state: Florida
city: Deerfield Beach
country: United States
state: Florida
city: Fort Myers
country: United States
state: Florida
city: Hallandale Beach
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Hollywood
country: United States
state: Florida
city: Largo
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Naples
country: United States
state: Florida
city: Orange City
country: United States
state: Florida
city: Pompano Beach
country: United States
state: Florida
city: Port Charlotte
country: United States
state: Florida
city: Sarasota
country: United States
state: Florida
city: Sunrise
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: West Palm Beach
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Savannah
country: United States
state: Georgia
city: Honolulu
country: United States
state: Hawaii
city: Chicago
country: United States
state: Illinois
city: Indianapolis
country: United States
state: Indiana
city: Lexington
country: United States
state: Kentucky
city: Boston
country: United States
state: Massachusetts
city: West Yarmouth
country: United States
state: Massachusetts
city: Grand Rapids
country: United States
state: Michigan
city: Saint Louis
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: Dover
country: United States
state: New Hampshire
city: Manchester Township
country: United States
state: New Jersey
city: Piscataway
country: United States
state: New Jersey
city: Princeton
country: United States
state: New Jersey
city: Stratford
country: United States
state: New Jersey
city: Toms River
country: United States
state: New Jersey
city: Albuquerque
country: United States
state: New Mexico
city: Brooklyn
country: United States
state: New York
city: New Hyde Park
country: United States
state: New York
city: New York
country: United States
state: New York
city: Cincinnati
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Eugene
country: United States
state: Oregon
city: Havertown
country: United States
state: Pennsylvania
city: Jenkintown
country: United States
state: Pennsylvania
city: Moon
country: United States
state: Pennsylvania
city: Philadelphia
country: United States
state: Pennsylvania
city: Beaufort
country: United States
state: South Carolina
city: Greer
country: United States
state: South Carolina
city: North Charleston
country: United States
state: South Carolina
city: Bellaire
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Wichita Falls
country: United States
state: Texas
city: Bennington
country: United States
state: Vermont
city: Burlington
country: United States
state: Vermont
city: Middleton
country: United States
state: Wisconsin
Study officials:
affiliation: Takeda Global Research and Development
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References:
citation: McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020 Nov 15;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub4.